Non-Small Cell Lung Cancer

Latest News
May 14th 2025

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

March 28th 2025

Updated KRYSTAL-7 Data Show PFS Beyond 27 Months for Adagrasib Plus Pembro in First-Line Treatment of KRAS-Mutated NSCLC

February 20th 2025

NSCLC Advancements Offer Hope, but Disparities Persist

January 1st 2025

AI in Oncology: Opportunities and Challenges for NSCLC

December 27th 2024

ICYMI: Highlights From WCLC 2024

Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes

Get insight to advances in ALK+ NSCLC treatment, including long-term lorlatinib data, new therapy approvals, brain metastasis management, and evolving sequencing strategies with this series.

AJMC Peer Exchange logo
Video Interviews
View All
May 26th 2025

Long-Term Success: Educating and Supporting Patients on ALK Inhibitors

May 26th 2025

Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs

May 19th 2025

Navigating ALK Inhibitor Toxicities

May 19th 2025

Key Differences Among ALK Inhibitors

May 12th 2025

Applying Trial Data to Real-World Practice in ALK+ NSCLC

May 12th 2025

Choosing Wisely: Insights from an MAIC and eXalt3

May 5th 2025

Lorlatinib in Focus: Survival, Brain Metastases, and Beyond

May 5th 2025

The Evolution of ALK+ NSCLC Care

January 11th 2025

How Early Detection, Precision Medicine Can Impact Lung Cancer Outcomes

January 5th 2025

Combining Liquid and Tissue Biopsies for Better Lung Cancer Care

More News

Edgardo S. Santos, MD, FACP, FASCO
January 1st 2025

Revolutionizing Lung Cancer Care: The Impact of Liquid Biopsies

Skylar Jeremias
Edgardo S. Santos, MD, FACP, FASCO, highlighted how liquid biopsies are transforming lung cancer care by enabling faster, less invasive diagnostics, with key applications in early detection, predictive biomarker identification, treatment response monitoring, resistance mechanism assessment, and minimal residual disease detection.
Ryan Nguyen, MD
December 23rd 2024

Precision Oncology in NSCLC: Overcoming Patient Selection Barriers

Skylar Jeremias
Ryan Nguyen, DO, physician and researcher at the University of Illinois Chicago, emphasizes the transformative impact of immunotherapy in non–small cell lung cancer (NSCLC) and the need for precise biomarkers and equitable access to advanced treatments through systemic testing protocols.
NSCLC Thumbnail
December 20th 2024

Top 5 NSCLC Content for 2024

Maggie L. Shaw
Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data showing both setbacks in clinical trial results and advancements in screening recommendations for at-risk patients.
FDA approval. | Image Credit: Pawel - stock.adobe.com
December 19th 2024

Ensartinib Receives FDA Approval for ALK-Positive Locally Advanced or Metastatic NSCLC

Cameron Santoro
The FDA has approved ensartinib in adult patients with anaplastic lymphoma kinase (ALK)–positive locally advanced or metastatic non–small cell lung cancer (NSCLC) naive to ALK treatment.
Syringe and vials | Image credit: Aliaksandr Marko – stock.adobe.com
December 17th 2024

FDA Rejects Subcutaneous Amivantamab for NSCLC Over Manufacturing Concerns

Hayden E. Klein
Subcutaneous amivantamab joins a growing list of drugs receiving complete response letters due to manufacturing facility issues.
Lungs | image credit: istock photo
December 13th 2024

Updated Data Show Zongertinib Yields Responses in 71% With Previously Treated HER2-Mutated NSCLC

Mary Caffrey
The investigational oral HER2-specific tyrosine kinase inhibitor would address an unmet need in non–small cell lung cancer.
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
December 13th 2024

Next-Gen Strategies for Resistance in EGFR-Mutated Lung Cancer

Maggie L. Shaw
To conclude our interview with Joshua K. Sabari, MD, which focused on the approval of amivantamab plus lazertinib in the first line, he looks ahead to potential uses that could help to overcome treatment resistance in non–small cell lung cancer.
Bhuvana Sagar, MD
December 9th 2024

What Do Liquid Biopsies Add to Value-Based Cancer Care?

Hayden E. Klein
Payers want to make sure patients are getting biopsies done so they can get on the right therapies, said Bhuvana Sagar, MD, Oncology Consultants.
FDA approval with stamp | Image Credit: Surendra - stock.adobe.com
December 5th 2024

Zenocutuzumab Approved for NRG1+ NSCLC and Pancreatic Adenocarcinoma

Laura Joszt, MA
The accelerated approval was based on the results of the eNRGy trial of 64 patients with NRG1-positive non–small cell lung cancer and 30 patients with NRG1-positive pancreatic adenocarcinoma.
Divya Gupta, MD
December 4th 2024

Optimizing Outcomes in NSCLC With Precision Medicine and Teamwork

Skylar Jeremias
Divya Gupta, MD, assistant professor at the Northwestern University Feinberg School of Medicine, emphasized the transformative role of biomarker-driven therapies in advancing non–small cell lung cancer (NSCLC) treatment and highlighted the critical importance of multidisciplinary collaboration.
Immunotherapy | Image Credit: © kentoh-stock.adobe.com
December 2nd 2024

Baseline Response Rates Inform Immunotherapy Sequencing in NSCLC

Maggie L. Shaw
Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following treatment failure and disease progression after receipt of nivolumab and pembrolizumab.
Divya Gupta, MD
November 28th 2024

Revolutionizing NSCLC Care With Circulating Tumor DNA and MRD Assays

Skylar Jeremias
Divya Gupta, MD, assistant professor at Feinberg School of Medicine at Northwestern University, discussed the potential of using circulating tumor DNA and minimal residual disease (MRD) assays for personalized treatment in non–small cell lung cancer (NSCLC), while emphasizing the unmet need for effective second-line therapies for patients without driver mutations.
Lungcancertreatment | Image Credit: © Vitalii Vodolazskyi-stock.adobe.com
November 27th 2024

Durvalumab Underutilization Highlights Gaps in NSCLC Treatment Strategies

Maggie L. Shaw
Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients who have unresectable stage III non–small cell lung cancer (NSCLC).
Martin Dietrich, MD, PhD
November 21st 2024

Research Priorities Evolve With Amivantamab's Broader NSCLC Indications

Maggie L. Shaw
In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat non–small cell lung cancer (NSCLC).
FDA | Image Credit: © Artur-stock.adobe.com
November 18th 2024

FDA Approves Companion Diagnostic for Tepotinib in MET Exon 14 mNSCLC

Ashling Wahner
The FDA approved the FoundationOne Liquid CDx to identify patients with metastatic non–small cell lung cancer (mNSCLC) with MET exon 14 skipping alterations who may be eligible for tepotinib (Tepmetko; EMD Serono).
Lung cancer | Image Credit: © Crystal light - stock.adobe.com
November 15th 2024

Tailored Management Needed for Male Patients With NSCLC After Surgery

Maggie L. Shaw
Lung cancer is the top cause of cancer-related death worldwide.
Ticiana Leal, MD
November 13th 2024

Perioperative Strategies in NSCLC: Future Directions and Challenges

Rose McNulty Maggie L. Shaw
In the final part of our interview, Ticiana Leal, MD, Winship Cancer Institute, looks to the future of perioperative care in the non–small cell lung cancer (NSCLC) arena and the importance of risk stratifying patients.
Lung cancer image | Image Credit: © appledesign-stock.adobe.com
November 8th 2024

Sunvozertinib NDA Submitted to FDA for NSCLC

Chris Ryan
A new drug application (NDA) has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non–small cell lung cancer (NSCLC).
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
November 2nd 2024

Balancing Benefits and Risks of Amivantamab

Maggie L. Shaw
Principal treatment-related toxicities that come from amivantamab administration include skin-related reactions, higher risk of venous thrombolism, and infusion-related reactions.
Biomarker Scrabble tiles | Image Credit: © lexiconimages-stock.adobe.com
October 30th 2024

Improving Early-Stage Lung Cancer Care

Maggie L. Shaw
More than 80% of patients with lung cancer receive care in their communities, but this can leave them vulnerable to gaps in care quality and delivery.
Martin Dietrich, MD, PhD
October 24th 2024

Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib

Maggie L. Shaw
Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Umit Tapan, MD, Boston Medical Center
October 18th 2024

Expanding Access to NSCLC Innovations: Challenges and Opportunities

Maggie L. Shaw
The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and improving treatment access, in particular for immunotherapy and targeted treatments.
FDA approved | Image Credit: © wladimir1804 -stock.adobe.com
October 16th 2024

FDA Approves Optune Lua Device in NSCLC

Maggie L. Shaw
Optune Lua creates tumor-treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 inhibitors or docetaxel to treat metastatic non–small cell lung cancer (NSCLC) that has not responded to platinum-based treatment.
Emory Winship Cancer Institute | Image: Emory
October 14th 2024

In Cancer Care, Innovation Comes at a Cost

Rose McNulty
Ticiana Leal, MD, Emory Winship Cancer Institute
October 12th 2024

Early Biomarker Testing Key for Perioperative NSCLC Success

Rose McNulty Maggie L. Shaw
Ticiana Leal, MD, Winship Cancer Institutes, explains the importance of biomarker testing and multidisciplinary conversations while caring for patients with early-stage non–small cell lung cancer (NSCLC).
LC and breathing | Image Credit: © Cozine-stock.adobe.com
October 10th 2024

Breathomics: A Low-Cost Solution for Early Lung Cancer Diagnosis?

Kimberly Rath, PharmD
Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may distinguish between patients with the disease and healthy individuals.
FDA Approval | Image Credit: © BHM-stock.adobe.com
October 4th 2024

Nivolumab Approved as Neoadjuvant, Adjuvant Therapy for NSCLC by FDA

Maggie L. Shaw
The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable non–small cell lung cancer (NSCLC) in the neoadjuvant and adjuvant settings.
Joshua K. Sabari, MD, NYU Langone
September 30th 2024

Amivantamab Presents an Exciting Treatment Opportunity in NSCLC

Maggie L. Shaw
In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals from the FDA for use in non–small cell lung cancer (NSCLC).
Martin Dietrich, MD, PhD, Cancer Care Centers of Brevard
September 27th 2024

Amivantamab Accolades Add Up for NSCLC

Maggie L. Shaw
On September 19, the FDA handed down its third amivantamab (Rybrevant; Johnson & Johnson) approval for 2024 in non–small cell lung cancer (NSCLC), giving the third-generation tyrosine kinase inhibitor its fourth approval overall.
FDA | Image Credit: © wladimir1804-stockk.adobe.com
September 26th 2024

FDA Approves Osimertinib in Stage III NSCLC

Maggie L. Shaw
The approval means an additional indication for osimertinib (Tagrisso; AstraZeneca) for adult patients who have unresectable stage III non–small cell lung cancer (NSCLC) with EGFR mutation.
12345>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo